TP53 and ovarian cancer: Limiting follow up to 24 months makes this data even more pronounced [HR 6.09 (1.52–24.51), p<0.01] suggesting that p53 null HGSOCs are a sub-group of ovarian cancer with a particularly adverse presentation.